EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

Recruiting now

Conditions studied: Hormone Receptor Positive Breast Cancer

In brief

This phase II, open-label, single-arm, study investigates the clinical benefit of everolimus combined with endocrine therapy (ET) in hormone receptor-positive (HR+), metastatic breast cancer (MBC) patients who progressed on prior PI3K inhibitor therapy (+ ET). The trial aims to determine if sequential inhibition of the PI3K/AKT/mTORC1 pathway retains efficacy post-PI3K inhibitor resistance, hypothesizing that everolimus will demonstrate a response rate exceeding the historical 9.5% observed in the BOLERO2 trial.

Key facts

Study ID

NCT07646171

Run by

Tel-Aviv Sourasky Medical Center

People needed

19

Starts

2022-09-01

Expected to finish

2027-12-31

Last updated by the study team

2026-06-12

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HR+MBC with PI3Kmut Post CDK 4/6+ET Post PI3K inhibitor+ET

You may not qualify if…

• Women who didn't receive anti-PI3K

Where it is running

• Ichilov-Sourasky Medical Center — Tel Aviv, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.